In line with this, our results identified IL‐17 as the responsible initiator of the tumor‐promoting miR‐142‐5p‐SDH‐axis further supporting the idea of Th17‐based immunotherapeutic approaches by using the approved antibodies targeting Th17 cells in cervical cancers and potentially other Th17‐infiltrated cancers. This evidence concerns the gene IL17A and neoplasm.